8622 Background: Sevabertinib, a potent, reversible, oral tyrosine kinase inhibitor, received FDA accelerated approval for pretreated patients with advanced NSCLC harboring HER2 tyrosine kinase domain-activating mutations. Sevabertinib demonstrated significant antitumor activity and manageable safety in patients with HER2 -mutant NSCLC who had previously received treatment (Cohort D) or were treatment-naïve (Cohort F) in the ongoing, open-label, multicenter, Phase I/II SOHO-01 trial (NCT05099172